<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>STREPTOMYCIN- streptomycin sulfateÂ injection, powder, lyophilized, for solutionÂ </strong><br>X-GEN Pharmaceuticals, Inc.<br></p></div>
<h1>Streptomycin for Injection, USP<br><br>Rx Only<br><br>1 gram*/vial<br>*Each vial contains Streptomycin Sulfate<br>USP equivalent to 1 gram Streptomycin<br><br>For Intramuscular Use</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c6c39bc-e293-4507-8dcf-879a78bc950a"></a><a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Warning">
<a name="LINK_154e34e6-8b97-410a-b094-086cb5e542ce"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First">Â Â Â Â THE RISK OF SEVERE NEUROTOXIC REACTIONS IS SHARPLY INCREASED IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span> OR PRE-RENAL <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">AZOTEMIA</span>. THESE INCLUDE DISTURBANCES OF VESTIBULAR AND COCHLEAR FUNCTION, OPTIC NERVE DYSFUNCTION, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">PERIPHERAL NEURITIS</span>, <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">ARACHNOIDITIS</span>, AND <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">ENCEPHALOPATHY</span> MAY ALSO OCCUR. THE INCIDENCE OF CLINICALLY DETECTABLE, IRREVERSIBLE VESTIBULAR DAMAGE IS PARTICULARLY HIGH IN PATIENTS TREATED WITH STREPTOMYCIN.</p>
<p>Â Â Â Â RENAL FUNCTION SHOULD BE MONITORED CAREFULLY; PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> AND/OR NITROGEN RETENTION SHOULD RECEIVE REDUCED DOSES. THE PEAK SERUM CONCENTRATION IN INDIVIDUALS WITH KIDNEY DAMAGE SHOULD NOT EXCEED 20 TO 25 MCG/ML.</p>
<p>Â Â Â Â THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH STREPTOMYCIN SULFATE, INCLUDING NEOMYCIN, KANAMYCIN, GENTAMICIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, POLYMYXIN B, COLISTIN, TOBRAMYCIN AND CYCLOSPORINE SHOULD BE AVOIDED.</p>
<p>Â Â Â Â THE <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span> OF STREPTOMYCIN CAN RESULT IN <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">RESPIRATORY PARALYSIS</span> FROM NEUROMUSCULAR BLOCKAGE, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER THE USE OF ANESTHESIA OR MUSCLE RELAXANTS.</p>
<p>Â Â Â Â THE ADMINISTRATION OF STREPTOMYCIN IN PARENTERAL FORM SHOULD BE RESERVED FOR PATIENTS WHERE ADEQUATE LABORATORY AND AUDIOMETRIC TESTING FACILITIES ARE AVAILABLE DURING THERAPY.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ba03d5d9-ba1f-4799-bd5a-7b4aa07f450d"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Streptomycin is a water-soluble aminoglycoside derived from <span class="Italics">Streptomyces griseus</span>. It is marketed as the sulfate salt of streptomycin. The chemical name of streptomycin sulfate is D-Streptamine, <span class="Italics">O</span>-2-deoxy-2-(methylamino)-Î±-L-glucopyranosyl-(1â†’2)-<span class="Italics">O</span>-5-deoxy-3-<span class="Italics">C</span>-formyl-Î±-L-lyxofuranosyl-(1â†’4)-<span class="Italics">N,N</span><span class="Sup">1</span>-bis(aminoiminomethyl)-,sulfate (2:3) (salt). The molecular formula for Streptomycin Sulfate is (C<span class="Sub">21</span>H<span class="Sub">39</span>N<span class="Sub">7</span>O<span class="Sub">12</span>)<span class="Sub">2</span> -3H<span class="Sub">2</span>SO<span class="Sub">4</span> and the molecular weight is 1457.41. It has the following structural formula:</p>
<div class="Figure">
<img alt="strp-formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&amp;name=streptomycin-for-injection-usp-1.jpg"><p class="MultiMediaCaption">structural formula</p>
</div>
<p>Streptomycin for Injection USP, equivalent to 1 gram streptomycin /vial is supplied as a sterile nonpyrogenic lyophillized cake for intramuscular use after reconstitution. The lyophillized cake may reduce to a powder during shipping.</p>
<p>After reconstitution the pH range for Streptomycin for Injection USP should be between 4.5 and 7 in a solution containing 200 mg of streptomycin activity per mL.</p>
<p>*Each vial of Streptomycin for Injection contains streptomycin sulfate equivalent to 1 gram of streptomycin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_ca9ced7c-f303-4361-aab4-e4c0a6cdeae5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following intramuscular injection of 1 g of streptomycin as the sulfate, a peak serum level of 25 to 50 mcg/mL is reached within 1 hour, diminishing slowly to about 50 percent after 5 to 6 hours.</p>
<p>Appreciable concentrations are found in all organ tissues except the brain. Significant amounts have been found in pleural fluid and tuberculous cavities. Streptomycin passes through the placenta with serum levels in the cord blood similar to maternal levels. Small amounts are excreted in milk, saliva, and sweat.</p>
<p>Streptomycin is excreted by glomerular filtration. In patients with normal kidney function, between 29% and 89% of a single 600 mg dose is excreted in the urine within 24 hours. Any reduction of glomerular function results in decreased excretion of the drug and concurrent rise in serum and tissue levels</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8947500e-7987-4b71-b735-ba38304603ef"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Streptomycin sulfate is a bactericidal antibiotic. It acts by interfering with normal protein synthesis.</p>
<p>Streptomycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (See<a href="#LINK_ba9aa6de-091b-4d3a-a3dc-5f9eaebc602a"> INDICATIONS AND USAGE</a>.):</p>
<ul class="Square">
<li><p class="First"><span class="Italics">Brucella</span> (<span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">brucellosis</span>),</p></li>
<li><p class="First"><span class="Italics">Calymmatobacterium granulomatis</span> (donovanosis, <span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">granuloma inguinale</span>),</p></li>
<li><p class="First"><span class="Italics">Escherichia coli, Proteus spp., Aerobacter aerogenes, Klebsiella pneumoniae,</span> and <span class="Italics">Enterococcus faecalis</span> in <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>,</p></li>
<li><p class="First"><span class="Italics">Francisella tularensis</span>,</p></li>
<li><p class="First"><span class="Italics">Haemophilus ducreyi</span> (<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>),</p></li>
<li><p class="First"><span class="Italics">Haemophilus influenzae </span>(in respiratory, endocardial, and meningeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> - concomitantly with another antibacterial agent),</p></li>
<li><p class="First"><span class="Italics">Klebsiella pneumoniae </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (concomitantly with another antibacterial agent),</p></li>
<li><p class="First"><span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>,</p></li>
<li><p class="First"><span class="Italics">Pasteurella pestis</span></p></li>
<li><p class="First"><span class="Italics">Streptococcus</span> viridans, <span class="Italics">Enterococcus faecalis</span> (in endocardial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> - concomitantly with penicillin).</p></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a535a89e-65ed-4939-9bb4-8ffe56753bb2"></a><a name="section-3.2"></a><p></p>
<h2>SUSCEPTIBILITY TESTS: Diffusion Techniques</h2>
<p class="First">Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents. One such standard procedure 1Â which has been recommended for use with disks to test susceptibility of organisms to streptomycin uses the 10 mcg streptomycin disk. Interpretation involves the correlation of the diameter obtained in the disk test with the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) for streptomycin.</p>
<p>Reports from the laboratory giving results of the standard single disk susceptibility test with a 10 mcg streptomycin disk should be interpreted according to the following criteria:</p>
<p>Interpretive Criteria for EnterobacteriaceaeÂ </p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">Â Zone Diameter (mm)Â Â Â Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Interpretation</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â â‰¥15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â (S) Susceptible</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 11-12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â (I) Intermediate</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â â‰¤10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â (R) Resistant</td>
</tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to respond to monotherapy with streptomycin. A report of â€œIntermediateâ€? indicates that the result be considered equivocal, and, if the organism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretations. A report of â€œResistantâ€? indicates that achievable drug concentrations are unlikely to be inhibitory and other therapy should be selected.</p>
<p>Standardized procedures require the use of laboratory control organisms. The 10 mcg streptomycin disk should give the following zone diameter<span class="Sup">2</span>:</p>
<p>Acceptable Control RangesÂ </p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â Organism</td>
<td class="Botrule Lrule Rrule Toprule">Â Zone Diameter (mm)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â E. <span class="Italics">coli </span>ATCC 25922</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 12-20</td>
</tr>
</tbody>
</table>
<p>Interpretive Criteria for Agents of BioterrorismÂ </p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2">OrganismÂ Â Â Â Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">MIC Range (mcg/mL)Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â  (S) Susceptible</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(I) Intermediate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â (R) Resistant</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Italics">Yersinia pestis </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â â‰¤4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â  8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â â‰¥16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Italics">Francisella tularensis </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤8</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" rowspan="2"><p class="First"><span class="Italics">There are no Intermediate or Resistant criteria</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Brucella </span>spp.</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤8</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_ba9aa6de-091b-4d3a-a3dc-5f9eaebc602a"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Streptomycin is indicated for the treatment of individuals with moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptibile <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of microorganisms in the specific conditions listed below:</p>
<ol class="Arabic">
<li><p class="First">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>: The Advisory Council for the Elimination of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Streptomycin is also indicated for therapy of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> has become more complex as a consequence of increasing rates of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> and concomitant <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. Additional consultation from experts in the treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> may be desirable in those settings.</p></li>
<li>
<p class="First">Non-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: The use of streptomycin should be limited to the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents.</p>
<ol class="LittleAlpha">
<li><p class="First"><span class="Italics">Pasteurella pestis</span> (<span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">plague</span>),</p></li>
<li><p class="First"><span class="Italics">Francisella tularensis</span> (tularemia),</p></li>
<li><p class="First"><span class="Italics">Brucella</span>,</p></li>
<li><p class="First"><span class="Italics">Calymmatobacterium granulomatis</span> (donovanosis, <span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">granuloma inguinale</span>),</p></li>
<li><p class="First"><span class="Italics">H. ducreyi</span> (<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>),</p></li>
<li><p class="First"><span class="Italics">H. influenzae </span>(in respiratory, endocardial, and meningeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>-concomitantly with another antibacterial agent),</p></li>
<li><p class="First"><span class="Italics">K. pneumoniae</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (concomitantly with another antibacterial agent),</p></li>
<li><p class="First"><span class="Italics">E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis</span> in <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>,</p></li>
<li><p class="First"><span class="Italics">Streptococcus </span>viridans, <span class="Italics">Enterococcus faecalis</span> (in endocardial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> -concomitantly with penicillin),</p></li>
<li><p class="First">Gram-negative bacillary <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> (concomitantly with another antibacterial agent).</p></li>
</ol>
</li>
</ol>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_cdb9e449-7549-4da0-8b36-07e6252b0ba6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">A history of clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to streptomycin is a contraindication to its use. Clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other aminoglycosides may contraindicate the use of streptomycin because of the known cross-sensitivity of patients to drugs in this class.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_862adbd1-c93d-4828-987a-84fc25cd81a0"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>: Both vestibular and auditory dysfunction can follow the administration of streptomycin. The degree of impairment is directly proportional to the dose and duration of streptomycin administration, to the age of the patient, to the level of renal function and to the amount of underlying existing auditory dysfunction. The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the co-administration of ethacrynic acid, mannitol, furosemide and possibly other diuretics.</p>
<p>The vestibulotoxic potential of streptomycin exceeds that of its capacity for cochlear toxicity. Vestibular damage is heralded by <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and disequilibrium. Early cochlear injury is demonstrated by the loss of high frequency hearing. Appropriate monitoring and early discontinuation of the drug may permit recovery prior to irreversible damage to the sensorineural cells.</p>
<p>Pregnancy: Streptomycin can cause fetal harm when administered to a pregnant woman. Because streptomycin readily crosses the placental barrier, caution in use of the drug is important to prevent <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> in the fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Streptomycin for Injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. <span class="Italics">difficile.</span></p>
<p>C. <span class="Italics">difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of C. <span class="Italics">difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. <span class="Italics">difjicile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C <span class="Italics">difjicile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_e5247b8e-2722-4230-b8f4-7e73451111b7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_7c5a26a1-261f-48dc-9b6c-960b9cdd79aa"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing streptomycin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Baseline and periodic caloric stimulation tests and audiometric tests are advisable with extended streptomycin therapy. <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, roaring noises, or a sense of fullness in the ears indicates need for audiometric examination or termination of streptomycin therapy or both.</p>
<p>Care should be taken by individuals handling streptomycin for injection to avoid skin sensitivity reactions. As with all intramuscular preparations, Streptomycin Sulfate Injection should be injected well within the body of a relatively large muscle and care should be taken to minimize the possibility of damage to peripheral nerves. (See <a href="#LINK_31b048e3-d74f-4a8a-9dc2-fd02777761f2">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Extreme caution must be exercised in selecting a dosage regimen in the presence of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. In severely uremic patients a single dose may produce high blood levels for several days and the cumulative effect may produce ototoxic sequelae. When streptomycin must be given for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time alkalinization of the urine may minimize or prevent renal irritation.</p>
<p>A syndrome of apparent central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, characterized by <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> and <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, occasionally <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and deep <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, has been reported in very young infants in whom streptomycin dosage had exceeded the recommended limits. Thus, infants should not receive streptomycin in excess of the recommended dosage.</p>
<p>In the treatment of venereal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">granuloma inguinale</span>, and <span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>, if concomitant <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, suitable laboratory procedures such as a dark field examination should be performed before the start of treatment, and monthly serologic tests should be done for at least four months.</p>
<p>As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be instituted.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_8c58219b-ad6a-4d33-aed9-853d812daaa5"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including streptomycin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When streptomycin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by streptomycin or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose ofthe antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_0d305791-d26d-4d98-aad1-c2d8a64e7b46"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the co-administration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_867548a6-a324-4567-ae5f-8a000553eb26"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Category D: See <a href="#LINK_862adbd1-c93d-4828-987a-84fc25cd81a0">WARNINGS</a> section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_4e2d1ef0-20be-47b6-bfc5-1e6f3c8e108b"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from streptomycin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_516eb071-261c-4a96-99d4-678c5a493a32"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">(See <a href="#LINK_31b048e3-d74f-4a8a-9dc2-fd02777761f2">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_73ac1e89-f1a7-43e2-bbcd-24cfddcf63db"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following reactions are common: vestibular <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>); <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of face; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>; and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p>The following reactions are less frequent: cochlear <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> (<span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>); <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>; <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>; and <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>.</p>
<p>Vestibular dysfunction resulting from the parenteral administration of streptomycin is cumulatively related to the total daily dose. When 1.8 to 2 g/day are given, symptoms are likely to develop in the large percentage of patients - especially in the elderly or patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> - within four weeks. Therefore, it is recommended that caloric and audiometric tests be done prior to, during, and following intensive therapy with streptomycin in order to facilitate detection of any vestibular dysfunction and/or impairment of hearing which may occur.</p>
<p>Vestibular symptoms generally appear early and usually are reversible with early detection and cessation of streptomycin administration. Two to three months after stopping the drug, gross vestibular symptoms usually disappear, except from the relative inability to walk in total darkness or on very rough terrain.</p>
<p>Although streptomycin is the least nephrotoxic of the aminoglycosides, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> does occur rarely.</p>
<p>Clinical judgment as to termination of therapy must be exercised when side effects occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_31b048e3-d74f-4a8a-9dc2-fd02777761f2"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fdbad81f-59c3-424d-a638-312710be09e9"></a><a name="section-9.1"></a><p></p>
<h2>Intramuscular Route Only</h2>
<p class="First"><span class="Bold">Adults:</span> The preferred site is the upper outer quadrant of the buttock, (i.e., gluteus maximus), or the mid-lateral thigh.</p>
<p><span class="Bold">Children:</span> It is recommended that intramuscular injections be given preferably in the mid-lateral muscles of the thigh. In infants and small children the periphery of the upper outer quadrant of the gluteal region should be used only when necessary, such as in burn patients, in order to minimize the possibility of damage to the sciatic nerve.</p>
<p>The deltoid area should be used only if well developed such as in certain adults and older children, and then only with caution to avoid <span class="product-label-link" type="condition" conceptid="136865" conceptname="Injury of radial nerve">radial nerve injury</span>. Intramuscular injections should not be made into the lower and mid-third of the upper arm. As with all intramuscular injections, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> is necessary to help avoid inadvertent injection into a blood vessel.</p>
<p>Injection sites should be alternated. As higher doses or more prolonged therapy with streptomycin may be indicated for more severe or fulminating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, etc.), the physician should always take adequate measures to be immediately aware of any toxic signs or symptoms occurring in the patient as a result of streptomycin therapy.</p>
<p>1.Â  <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">TUBERCULOSIS</span>: The standard regimen for the treatment of drug susceptible <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> has been two months of INH, rifampin and pyrazinamide followed by four months of INH and rifampin (patients with concomitant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and HIV may require treatment for a longer period). When streptomycin is added to this regimen because of suspected or proven <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> (see<a href="#LINK_ba9aa6de-091b-4d3a-a3dc-5f9eaebc602a"> INDICATIONS AND USAGE </a>section), the recommended dosing for streptomycin is as follows:</p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td valign="top">Â </td>
<th class="Botrule Lrule Rrule Toprule" valign="top">Daily</th>
<th class="Botrule Lrule Rrule Toprule" valign="top">Twice WeeklyÂ </th>
<th class="Botrule Lrule Rrule Toprule" valign="top">Thrice Weekly</th>
</tr></tbody>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">Children</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 20-40 mg/kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 25-30 mg/kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 25-30 mg/kg</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="right" valign="top">Â Max</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 g</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 1.5 g</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.5 g</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">Adults</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15 mg/kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25-30 mg/kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25-30 mg/kg</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="right" valign="top">Â Max</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 g</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 1.5 g</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.5 g</td>
</tr>
</tbody>
</table>
<p>Streptomycin is usually administered daily as a single intramuscular injection. A total dose of not more than 120 g over the course of therapy should be given unless there are no other therapeutic options. In patients older than 60 years of age the drug should be used at a reduced dosage due to the risk of increased toxicity. (See <a href="#LINK_154e34e6-8b97-410a-b094-086cb5e542ce">BOXED WARNING</a>.)</p>
<p>Therapy with streptomycin may be terminated when toxic symptoms have appeared, when impending toxicity is feared, when organisms become resistant, or when full treatment effect has been obtained. The total period of drug treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is a minimum of 1 year; however, indications for terminating therapy with streptomycin may occur at any time as noted above.</p>
<p>2. Â TULAREMIA: One to 2 g daily in divided doses for 7 to 14 days until the patient is afebrile for 5 to 7 days.</p>
<p>3.Â  <span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">PLAGUE</span>: Two grams of streptomycin daily in two divided doses should be administered intramuscularly. A minimum of 10 days of therapy is recommended.</p>
<p>4.Â  <span class="product-label-link" type="condition" conceptid="4116649" conceptname="Bacterial endocarditis">BACTERIAL ENDOCARDITIS</span>:</p>
<p>a<span class="Italics">. Streptococcal <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span></span>; in penicillin-sensitive alpha and non-hemolytic streptococcal <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> (penicillin MIC<span class="Underline">&lt;</span>0.1 mcg/mL),Â streptomycin may be used for 2-week treatment concomitantly with penicillin. The streptomycin regimen is 1 g b.i.d. for the first week, and 500 mg b.i.d. for the second week. If the patient is overÂ  60 years of age, the dosage should be 500 mg b.i.d. for the entire 2- week period.</p>
<p>b.<span class="Italics"> Enterococcal <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span></span>: Streptomycin in doses of 1 g b.i.d. for 2 weeks and 500 mg b.i.d. for an additional 4 weeks is given in combination with penicillin. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> may require termination of the streptomycin prior to completion of the 6-week course of treatment.</p>
<p>5.Â  CONCOMITANT USE WITH OTHER AGENTS: For concomitant use with other agents to which the infecting organism is also sensitive: Streptomycin is considered a secondline agent for the treatment of gram-negative bacillary bactermia, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>; <span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">brucellosis</span>; <span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">granuloma inguinale</span>; <span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p>For adults: 1 to 2 grams in divided doses every six to twelve hours for moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Doses should generally not exceed 2 grams per day.</p>
<p>For children: 20 to 40 mg/kg/day (8 to 20 mg/lb/day) in divided doses every 6 to 12 hours. (Particular care should be taken to avoid excessive dosage in children).</p>
<p>The dry lyophillized cake is dissolved by adding Water for Injection USP in an amount to yield the desired concentration as indicated in the following table:</p>
<table>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="right" valign="top">Approx. Conc. mg/mL</th>
<th class="Botrule Lrule Rrule Toprule" align="right" valign="top">Volume (mL) of SolventÂ </th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">Â 200</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 4.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 250</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 3.2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â 400</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1.8</td>
</tr>
</tbody>
</table>
<p>Sterile reconstituted solutions should be protected from light and may be stored at room temperature for one week without significant loss of potency</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_fcb32c50-6808-4087-9cf3-4d1ceb9ef71e"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Streptomycin for Injection USP is available in single vials containing 1 gram NDC 39822-0706-1 packaged asÂ boxes of ten vials NDC 39822-0706-2.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_c415a861-5b17-424e-b3a2-e5960913df32"></a><a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store dry powder under controlled room temperature 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">PROTECT FROM LIGHT</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_ffc6641f-a740-4127-a553-d76c7838d3c4"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><span class="Sup">1</span> Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptability Tests </p>
<p>Approved Standard-Tenth Edition. CLSI Document M02-A10. Vol. 29 No. 1, CLSI, Wayne, PA 2009.</p>
<p><span class="Sup">2</span> Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptability Testing;</p>
<p>Twenty-First Informational Supplement. CLSI Document M100-S21 Vol. 31 No. 1, CLSI, Wayne, PA 2011.</p>
<p>Manufactured for:</p>
<p>X-Gen Pharmaceuticals, Inc.</p>
<p>Big Flats, NY 14814</p>
<p>RevisedÂ December 2012</p>
<p>STRP-PI-01</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_81c68581-1411-46c9-87d4-7b472927f803"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 39822-0706-1<br>Streptomycin for Injection, USP<br>1 gram*/ vial <br>For Intramuscular Use<br>Rx Only<br>1 Vial<br>X-GEN Pharmaceuticals, Inc.<br>Â </p>
<div class="Figure">
<img alt="strp-exla-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&amp;name=streptomycin-for-injection-usp-2.jpg"><p class="MultiMediaCaption">vial label</p>
</div>
<p>NDC 39822-0706-2<br>Streptomycin for Injection, USP<br>1 gram*/ vial <br>For Intramuscular Use<br>Rx Only<br>10 Vial carton<br>X-GEN Pharmaceuticals, Inc.<br><img alt="strp-exla-10pkcarton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&amp;name=streptomycin-for-injection-usp-3.jpg"><p class="MultiMediaCaptionNotCentered">10 pack carton</p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>STREPTOMYCINÂ 		
					</strong><br><span class="contentTableReg">streptomycin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:39822-0706</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>STREPTOMYCIN SULFATE</strong> (STREPTOMYCIN) </td>
<td class="formItem">STREPTOMYCIN</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-0706-2</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-0706-1</td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA064210</td>
<td class="formItem">06/30/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>X-GEN Pharmaceuticals, Inc.
							(790169531)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Exela Pharma Sciences, LLC</td>
<td class="formItem"></td>
<td class="formItem">831274399</td>
<td class="formItem">ANALYSIS(39822-0706), LABEL(39822-0706), MANUFACTURE(39822-0706), PACK(39822-0706)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>061a6d1c-2095-4a31-97d8-36b144d6ed4f</div>
<div>Set id: abd1f64e-4283-4370-aae8-3666316aa36e</div>
<div>Version: 8</div>
<div>Effective Time: 20130514</div>
</div>
</div>Â <div class="DistributorName">X-GEN Pharmaceuticals, Inc.</div></p>
</body></html>
